

# Contents

<b>1 Overview of Oncology Drug Development .....</b>	<b>1</b>
Laeq Malik and Steven Weitman	
<b>2 Overview of Oncology Biomarkers .....</b>	<b>29</b>
Mitsukuni Suenaga, Heinz-Josef Lenz, and Stefan J. Scherer	
<b>3 A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond .....</b>	<b>39</b>
Peng Zou, Sau Lee, Min Li, Lawrence Yu, and Duxin Sun	
<b>4 Controversies in Oncology: Size Based vs. Fixed Dosing .....</b>	<b>59</b>
Peter L. Bonate	
<b>5 Clinical QTc Assessment in Oncology .....</b>	<b>77</b>
Margaret R. Britto and Nenad Sarapa	
<b>6 Expediting Drug Development: Breakthrough Therapy Designation .....</b>	<b>107</b>
Carmen Ladner	
<b>7 Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors.....</b>	<b>121</b>
Ana Ruiz-Garcia and Kenji Yamazaki	
<b>8 Combination Development.....</b>	<b>151</b>
Annie St-Pierre, Maribel Reyes, and Vincent Duval	
<b>9 Role of Pharmacokinetics: Pharmacodynamics in Biosimilar Assessment .....</b>	<b>175</b>
Antonio da Silva and Didier Renard	
<b>10 Pharmacokinetics and Pharmacogenetics of Metronomics .....</b>	<b>189</b>
Nicolas André, Joseph Ciccolini, Marie Amélie Heng, and Eddy Pasquier	

<b>11</b>	<b>Modeling Tumor Growth in Animals and Humans: An Evolutionary Approach .....</b>	<b>209</b>
	Dean C. Bottino and Arijit Chakravarty	
<b>12</b>	<b>Practical Considerations for Clinical Pharmacology in Drug Development: A Survey of 44 FDA Oncology Approvals .....</b>	<b>237</b>
	Danny R. Howard	
<b>13</b>	<b>New Advancements in Exposure-Response Analysis to Inform Regulatory Decision Making .....</b>	<b>303</b>
	Liang Zhao, Li Hongshan, Anshu Marathe, Jingyu (Jerry) Yu, Dinko Rekić, Nitin Mehrotra, Vikram Sinha, and Yaning Wang	
	<b>Index.....</b>	<b>319</b>

Pharmacokinetics in Drug Development

Problems and Challenges in Oncology, Volume 4

Bonate, P.L.; Howard, D.R. (Eds.)

2016, XII, 330 p. 32 illus., 23 illus. in color., Hardcover

ISBN: 978-3-319-39051-2